Cellectis SA (CLLS) has released an update.
Cellectis SA, a leader in gene-editing biotechnology, has announced promising pre-clinical results for a new CAR T-cell therapy targeting aggressive triple-negative breast cancer (TNBC). The therapy, which employs TALEN®-edited MUC1 CAR T-cells, has shown potential for treating TNBC by overcoming the immunosuppressive tumor microenvironment and shrinking tumors at both local and distant sites. This innovative approach has revealed the possibility of low-dose, local administration to effectively combat tumor metastasis, offering a new beacon of hope for patients with limited treatment options.
For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.
